Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose

BACKGROUND: Dupilumab has been shown to improve clinical outcomes long term while reducing oral corticosteroid (OCS) dose in patients with severe OCS-dependent asthma. This post hoc analysis assesses the impact of OCS dose at baseline (≤10 or >10 mg·day(−1)) on long-term outcomes of dupilumab tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Domingo, Christian, Rabe, Klaus F., Price, David, Brusselle, Guy, Wechsler, Michael E., Xia, Changming, Pandit-Abid, Nami, Gall, Rebecca, Rowe, Paul J., Deniz, Yamo, Jacob-Nara, Juby A., Radwan, Amr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645323/
https://www.ncbi.nlm.nih.gov/pubmed/38020559
http://dx.doi.org/10.1183/23120541.00056-2023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645323/
https://www.ncbi.nlm.nih.gov/pubmed/38020559
http://dx.doi.org/10.1183/23120541.00056-2023

Ejemplares similares